<DOC>
	<DOCNO>NCT00327691</DOCNO>
	<brief_summary>The primary objective study determine degree additional reduction cardiovascular risk accrue patient lower LDL-C beyond currently accept minimum target level patient pre-existing CHD . Secondary objective include safety profile treatment strategy , cost-effectiveness , effect atherosclerotic-related event procedure , total mortality .</brief_summary>
	<brief_title>A Study Determine Degree Additional Reduction CV Risk Lowering LDL Below Minimum Target Levels</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Men woman age 3575 evident CHD Known hypersensitivity HMG COA reductase therapy , liver disease , evidence secondary hyperlipidemia</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Major cardiovascular event</keyword>
	<keyword>Major Coronary event</keyword>
	<keyword>Revascularization</keyword>
</DOC>